20

25

5



IT IS CLAIMED:

- A method of reducing injury to a cell exposed to an ischemic, or an hypoxic 1. condition, comprising
 - administering to the cell a $\psi\epsilon RACK$ peptide.
- 2. The method of claim 1, wherein said administering occurs prior to exposing the cell to said ischemic or hypoxic condition.
- The method of claim 2, wherein said administering prior to said ischemic or 3. 10 hypoxic condition is for a period of time of between about 1-180 minutes prior to said exposing.
 - The method of claim 1, wherein said administering occurs after exposing the cell 4. to said ischemic or hypoxic ¢ondition.
 - 5. The method of claim 4, wherein said administering after exposure to said ischemic or hypoxic condition occurs for between about 1-180 minutes after said ischemic or hypoxic condition.
 - 6. The method of claim 1, wherein said administering occurs during exposure of the cell to said ischemic or hypoxic condition
 - The method of claim 1 wherein said administering includes administering a 7. peptide having a sequence identified as SEQ ID NO:2.
 - 8. The method of claim 1, wherein said administering includes administering a peptide having a sequence selected from the group consisting of SEQ ID NOS:6-18.
- The method of claim 1, wherein said administering includes administering a 9. 30 ψεRACK peptide linked to a moiety effective to facilitate transport across a cell membrane.



- 10. The method of claim 9, wherein the moiety is selected from the group consisting of a Tat-derived peptide (SEQ ID NO:5), an Antennapedia carrier peptide (SEQ ID NO:3), and a polyarginine peptide.
- 11. The method of claim 1, wherein said administering includes administering the peptide by a route selected from the group consisting or intraveneous, parenteral, subcutaneous, inhalation, intranasal, sublingual, mucosal, and transdermal.
 - 12. A method of reducing injury to tissue exposed to an ischemic or an hypoxic condition, comprising

administering to the tissue a ψεRACK peptide.

- 13. The method of claim 12, wherein said administering occurs prior to exposing the tissue to said ischemic or hypoxic condition.
- 14. The method of claim 13, wherein said administering prior to said ischemic or hypoxic condition is for between about 1-180 minutes.
- 15. The method of claim 12, wherein said administering occurs after exposing the tissue to said ischemic or hypoxic condition.
- 16. The method of claim 15, wherein said administering after exposure to said ischemic or hypoxic condition occurs for between about 1-180 minutes after said ischemic or hypoxic condition.
- 17. The method of claim 12, wherein said administering occurs during exposure of the tissue to said ischemic or hypoxic condition.
- 18. The method of claim 12, wherein said administering includes administering a peptide having a sequence identified as SEQ ID NO:2.
- 19. The method of claim 12, wherein said administering includes administering a peptide having a sequence selected from the group consisting of SEQ ID NOS:6-18.



5

25

30



5

- 20. The method of claim 12, wherein said administering includes administering a $\psi\epsilon$ RACK peptide linked to a moiety effective to facilitate transport across a cell membrane.
- 21. The method of claim 12, wherein the moiety is selected from the group consisting of a Tat-derived peptide (SEQ ID NO:5), an Antennapedia carrier peptide (SEQ ID NO:3), and a polyarginine peptide.
 - 22. The method of claim 12, wherein said administering includes administering the peptide by a route selected from the group consisting or intraveneous, parenteral, subcutaneous, inhalation, intranasal, sublingual, mucosal, and transdermal.
 - 23. The method of claim 12 wherein said administering is to a tissue that is a whole organ ex vivo.
 - 24. The method of claim 12 wherein said administering is to a tissue that is a whole organ *in vivo*.
 - 25. The method of claim 23 or 24, wherein said organ is selected from the group consisting of heart, lung, liver, brain, and kidney.
 - 26. The method of claim 24, wherein said administering is by infusion through coronary arteries to an intact heart.

